The efficacy of axitinib as a first‐line treatment for metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

The efficacy of axitinib as a first‐line treatment for metastatic renal cell carcinoma

Published:2020-03-04 Issue:4 Volume:16 Page:241-246
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Kameda Tomohiro¹^ORCID,Takayama Tatsuya¹,Sugihara Toru¹,Takeshima Saki¹,Yamazaki Masahiro¹,Komatsubara Maiko¹,Kamei Jun¹,Fujisaki Akira¹,Ando Satoshi¹,Kurokawa Shinsuke¹,Fujimura Tetsuya¹

Affiliation:

1. Department of UrologyJichi Medical University Tochigi Japan

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13323

Reference26 articles.

1. International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality

2. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

3. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

4. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

5. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, synthesis and biological characteristics of pyrazolo[3,4-d]pyrimidine derivatives as potential VEGFR-2 inhibitors;Future Medicinal Chemistry;2022-11

2. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system;Expert Opinion on Drug Safety;2021-12-31